Aug 2026· MedComm· Vol 7· 0 citations· 260 references
Medicine
TL;DR
This review analyzes how the ubiquitin–proteasome system, autophagy–lysosome pathway, endoplasmic reticulum stress‐induced unfolded protein response signaling, and molecular chaperone networks are differentially reconfigured in cancer and cardiac tissues, influencing tumor survival, therapeutic susceptibility, and cardiovascular dysfunction.
Abstract
Cancer and cardiovascular diseases, the primary causes of mortality globally, are increasingly understood as biologically interconnected rather than distinct pathologies. Recent evidence indicates that protein homeostasis (proteostasis) functions as a crucial molecular link connecting tumor progression, therapeutic resistance, cardiac remodeling, and treatment‐related cardiotoxicity. Proteostasis, which encompasses the cellular processes of protein synthesis, folding, quality control, and degradation, dictates tissue adaptation to chronic stress. Notably, the adaptive mechanisms that allow tumor cells to endure proteotoxic stress and resist therapy are often vital for maintaining cardiac structure and function. Thus, tumor control and cardiovascular injury may be divergent outcomes of a common stress–response framework. In this review, we propose proteostasis as a comprehensive framework for understanding the cancer–cardiovascular interface. We analyze how the ubiquitin–proteasome system, autophagy–lysosome pathway, endoplasmic reticulum stress‐induced unfolded protein response signaling, and molecular chaperone networks are differentially reconfigured in cancer and cardiac tissues, influencing tumor survival, therapeutic susceptibility, and cardiovascular dysfunction. Additionally, we explore the translational implications of proteostasis dysregulation, including mechanisms of anticancer therapy‐induced cardiotoxicity, emerging biomarkers, cardioprotective strategies, and opportunities for precision cardio‐oncology. By conceptualizing efficacy and toxicity as interconnected outcomes of shared proteostasis biology, this review establishes a foundation for developing therapies that optimize cancer control while safeguarding cardiovascular health.
Current and emerging therapeutic strategies aimed at disrupting proteostasis networks, including proteasome inhibitors, UPR-targeted agents, chaperone-directed therapies, and novel targeted protein degradation technologies are examined.
This review series highlights the breadth and impact of European research in the field of proteostasis, spanning fundamental mechanisms, organelle‐specific quality control pathways, and emerging therapeutic opportunities and showcases the collaborative efforts that have strengthened the European proteostasis community.
How cells balance this tightrope between adaptation and cell death in the context of cancer is dissected, and how UPR signaling drives angiogenesis, metastasis, immune-evasion, and chemoresistance is explored before finally discussing its therapeutic potential.
This Editorial highlights hierarchical mitochondrial quality control and defines directionality, spatial context, temporal order, and flux within these interactions will be essential for converting descriptive interaction maps into causal physiology and selective therapies.
Motohiro Nishida· Journal of Physiological Sci...· 0 citations
This review examines metabolism–inflammation crosstalk in cardiovascular disease by linking core inflammatory pathways with metabolic sensors, immune-cell metabolic reprogramming and signaling metabolites, then comparing disease-specific mechanisms in myocardial infarction/ischemia–reperfusion injury, heart failure, at...
Autophagy serves as a crucial modulator of myocardial fibrosis through multiple interconnected molecular pathways, underscoring the need for further research to translate these mechanisms into effective clinical interventions.
Nuo-Tong Wang, Wan-Qing Xu, Yan Hu et al.· Canadian Journal of Physiolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.